This research demonstrates enhanced anticoagulant properties in magnesium ferrites, indicating potential biomedical applications.
Mg1-xZnxFe2O4, Mg1-xCoxFe2O4, and Mg1-xNixFe2O4 ferrites synthesized by using Co-precipitation method. The structural characterizations of these samples were carried out and the formation of single phase ferrite was substantiated through powder X-ray diffraction (XRD), which revealed single phase cubic spinel structure, with lattice constants ranging from 8.323 to 8.353 Å, 8.328 to 8.351 Å, and 8.315 to 8.366 Å for the Mg1-xZnxFe2O4, Mg1-xCoxFe2O4, and Mg1-xNixFe2O4 ferrites, respectively. Surface morphology was investigated through scanning electron microscopic (SEM) analysis. The grain sizes for the Mg1-xZnxFe2O4, Mg1-xCoxFe2O4, and Mg1-xNixFe2O4 ferrites were found to vary from 3.745 to 4.227 μm, 4.034 to 5.08 μm, and 3.946 to 4.887 μm, respectively. The prepared samples showed high anticoagulant properties for the highest concentration of dopant proved by re-calcification time (RT), prothrombin time (PT) and platelet aggregation measurements. The higher RT, PT and Activated partial thromboplastin time (aPPT) values for the x=0.35 ferrites and lower platelet aggregation of the x=0.35 ferrites reveal that the anticoagulant properties of the x=0.35 ferrites are superior to those of the x=0.15 and x=0.25 ferrites for all samples.
No takes yet. Share an insight, caveat, or question.
Vishwarup et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: